Menu Close

Thrombotic Risk Markers

For individuals with a documented thrombotic event and a family history of thrombosis, testing coagulation factors is crucial for diagnosing the condition. Deficiencies of natural anticoagulants Antithrombin III, Protein C, Protein S, and factor mutations such as Activated Protein C Resistance may lead to venous thrombosis: Superficial Venous thrombosis (SVT), Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE). Specific coagulation factors released from the vascular endothelium, Thrombomodulin and Tissue Factor Pathway Inhibitor offer information about endothelial dysfuncti on. When hemostasis is disrupted because thrombi are not degraded, levels of Plasminogen and Plasminogen Activator Inhibitor Type 1 (PAI-1) may provide information to the state of the patient. The mechanisms of thrombosis in cancer patients involve a complex interacti on between the tumor cell, the patient, and the hemostatic system. Tumors may activate coagulation by their expression of Tissue Factor.

ACTICHROME® TF REF: 846 RUO

ACTICHROME® TFPI REF: 848 RUO

ACTICHROME® PLG REF: 851 RUO

ACTICHROME® AT-III REF: 838 510(K)

FDA 510(K)Cleared, Health Canada Registered

ACTICLOT® Protein C Resistance REF 840 | 840C IVD

CE Marked

ACTICLOT® Protein S REF: 843L IVD

CE Marked

ACTICLOT® C REF ACC-45

510(k), Health Canada Registered

IMUBIND® Tissue PAI-1 ELISA REF: 821 RUO

IMUBIND® Plasma PAI-1 ELISA REF 822 IVD

CE Marked, FDA 510(K)Cleared

IMUBIND® Thrombomodulin ELISA REF: 837 RUO

IMUBIND® Tissue Factor ELISA REF: 845 RUO

IMUBIND® uPA ELISA REF 894 RUO

IMUCLONE™ PAP ELISA REF: 603 RUO

IMUCLONE™ FPA ELISA REF: 635 RUO

IMUCLONE™ Free Protein S ELISA REF: 842 RUO

IMUCLONE™ Total TAFI ELISA REF: 873 RUO

SPECTROLYSE® PAI-1 REF: 101201 IVD

CE Marked, FDA 510(K)Cleared